CREDIT – Czech registry of IBD patients on biological therapy

Inflammatory bowel disease (IBD) is a group of inflammatory conditions of the colon and small intestine, typically affecting young people (aged 15 to 30). Crohn’s disease and ulcerative colitis are the principal types of IBD. Inflammatory bowel disease is rather difficult to manage, and often significantly affects the patients’ quality of life, including their work life and social activities. After exhausting all possibilities of conservative drug treatment (aminosalicylates, corticosteroids, immunosuppressive drugs), IBD patients are indicated for the administration of biological therapies. Biological therapy is the most effective option for IBD treatment, and is usually administered over long periods of time. In the Czech Republic, biological therapy for IBD treatment is administered in specialised centres.

Information obtained in this project can significantly contribute to improvements in the effectiveness and safety of biological therapy for IBD.

Primary objective of the project:

• to monitor the overall number of IBD patients treated with biological therapies in the Czech Republic.

Secondary objectives of the project:

• assessment of effectiveness of biological therapies,
• assessment of safety of biological therapies,
• assessment of therapeutic regimens,
• monitoring of duration of biological therapy in IBD patients.

Other important information:

• Expert guarantors: Prof. Milan Lukas, MD, PhD, and Martin Bortlik, MD, PhD (Czech Society of Gastroenterology)
• Partners: 34 specialised centres in the Czech Republic (you can find more detailed information on the website of the CREDIT project)